Paradigm Biopharmaceuticals has randomised and dosed the first participants in the Phase III clinical trial of injectable pentosan polysulfate sodium (PPS/Zilosul) for treating pain linked to knee osteoarthritis (kOA) in the US.
The randomisation of the first subject in the trial was carried out at Northwestern University, Chicago, US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNamed PARA_OA_002, the adaptive, randomised, double-blinded, placebo-controlled, multicentre, international trial is assessing the variation in pain and function following subcutaneous injections of PPS versus placebo in subjects with kOA pain.
It will have two stages to assess the dose and treatment effect of iPPS for kOA pain in trial subjects.
Stage 1 will include a Phase IIb dose selection and subjects will be randomised to receive one of the three iPPS dosing regimens or a placebo for six weeks.
Detecting the dose for usage in stage 2 and Paradigm’s confirmatory trial, PARA_OA_003 is the primary objective of stage 1 of the trial.
The dosage will be chosen based on an optimal balance of efficacy and safety.
In stage 2 of the trial, subjects will be randomised into a 1:1 ratio to receive the selected dosing regimen of PPS or placebo for six weeks.
Variation from baseline in WOMAC pain at Day 56 is the trial’s primary endpoint.
Secondary outcomes comprise variation from baseline at various time points till day 168 in WOMAC pain and function, quality of life and patient global impression of change.
Subject screening and enrolment in eight sites in Australia and 21 of the 56 chosen sites in the US are underway.
Activation of the remaining sites in the US will progress while sites in the UK and European Union will be launched throughout this year.
Paradigm chief medical officer and interim CEO Dr Donna Skerrett said: “To have our first subjects randomised in the US is an important milestone in the OA clinical programme.
“The Paradigm clinical team has been working tirelessly to initiate and activate sites throughout the US, and we are seeing a large number of subjects entering the screening phase throughout the US.”
In May 2019, the company reported positive real-world evidence of its iPPS in 205 kOA patients.
